FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a composition for treatment or prevention of a condition associated with mitochondrial dysfunction.The pharmaceutical composition for treatment or prevention of a condition associated with mitochondrial dysfunction that contains an effective amount of Urolithin, the specified condition having been selected from a group consisting of obesity, a reduced metabolic rate, the metabolic syndrome, diabetes mellitus, a cardiovascular disease, hyperlipidemia, a neurodegenerative disease, a cognitive function or disorder, mood disorders, stress and anxiety disorders; with Urolithin having been selected from ae group consisting of Urolithin A, Urolithin B, Urolithin C and Urolithin D.A method of treating or preventing a condition associated with mitochondrial dysfunction selected from the group consisting of obesity, decreased metabolic rate, the metabolic syndrome, diabetes mellitus, a cardiovascular disease, hyperlipidemia, a neurodegenerative disease, a cognitive function or disorder, mood disorder, stress and anxiety disorders, including: administering a therapeutically effective amount of urolithin to a subject that needs it, the urolithin having been selected from a group consisting of Urolithin A, Urolithin B, Urolithin C and Urolithin D.The use of Urolithin for the preparation of a pharmaceutical product for treatment or prevention of a condition associated with mitochondrial dysfunction selected from a group consisting of obesity, a reduced metabolic rate, the metabolic syndrome, diabetes mellitus, a cardiovascular disease, hyperlipidemia, a neurodegenerative disease, a cognitive function or disorder, mood disorders, stress and anxiety disorders; wherein the urolithin has been selected from a group consisting of Urolithin A, Urolithin B, Urolithin C and Urolithin D..
EFFECT: above compounds and compositions based on them are effective for treatment or prevention of a condition associated with mitochondrial dysfunction.
39 cl, 7 tbl, 21 ex, 49 dwg
